Mazen M El-Hammadi, Javier Vázquez Bourgon, Esther Berrocoso Dominguez, Benedicto Crespo Facorro, Irene Suárez Pereira, Lucía Martín Banderas
Cannabidiol (CBD) is a non-psychoactive cannabinoid that exhibits pain relief, anti-inflammatory, anti-oxidant, anti-tumor and neuroprotective properties. Furthermore, many studies have concluded that CBD exhibits several effects on both lipid and glucose metabolism through its action on various receptors and several metabolites. Accordingly, it has been found to decrease total cholesterol levels and to increase HDL levels, reduce intracellular lipid content and attenuate liver steatosis. Additionally, CBD has shown the ability to alleviate the symptoms of insulin resistance, minimize incidence of diabetes in mice and reduce the possibility of the metabolic syndrome among cannabis users. So, the objective of present work is to prepare CBD-loaded PLGA nanoparticles (NPs) and test their ability to increase glucose uptake and inhibit lipid accumulation in human HepG2 hepatocytes.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados